July decision date set for full approval of Eisai's Alzheimer's drug, with an adcomm coming too
The last time the FDA held an advisory committee meeting for an Alzheimer’s drug, Biogen’s Aduhelm (aducanumab) was unanimously rejected by the committee, and eventually …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
